News and Announcements
OpenDNA Inks Master Services Agreement With Expert System
- Published October 09, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- OpenDNA and Expert System entered into a master services agreement.
- Under the agreement, Expert System’s global marketing group can make use of OpenDNA’s Artificial Intelligence System (AIS) technology to personalise its lead generation marketing and customer experience.
- A successful agreement will entitle OpenDNA to a share in the annual recurring revenues from software subscription license fees and professional service fees.
OpenDNA recently entered into a master services agreement that will allow the marketing team of Expert System all over the world to make use of the former’s Artificial Intelligence System (AIS) technology.
The AIS system of OpenDNA is expected to help Expert System per-sonalise its processes for lead generation marketing and customer ex-perience resulting to a marketing-driven revenue, higher conversion rates and customer satisfaction.
“We’re proud to be selected by Expert System as they themselves are leaders in cognitive computing and machine learning fields. By including our leading AI technology into their business process we are certain it will help bring an increased level of personalisation to each user and drive tremendous value in marketing conversion rates, new customer acquisitions, and customer satisfaction,” OpenDNA’s Managing Director and CEO Jay Shah said.
Shah said they are excited to see the impact of OpenDNA’s A!-driver personalisation on the companies served by Expert System including Fortune 500 and Global 2000 as well as the different government agen-cies. This is a multi-billion dollar market opportunity for real-world and practical applications addressed by the AIS.
Expert System provides global enterprises with cognitive computing technologies for media and publishing, insurance, banking, government, energy and life sciences. Among its major customers are Chevron, ;, Bloomberg BNA, Eli Lilly, Shell, Zurich Insurance Group, Thomson Reu-ters and the U.S. Department of Agriculture and the U.S. Department of Justice.
Under the agreement, OpenDNA’s artificial intelligence technology will be integrated into the business processes of Expert System. The com-panies will then establish a joint trial scope, metrics and business cases, KPIs and use cases for the customer-facing operations of Expert Sys-tem.
“Artificial Intelligence and machine learning is driving a revolution in en-terprise business process automation.” Head of US Marketing Alicia Ha-rapko said. “For improving the customer experience processes in mar-keting, sales, and customer support, personalisation is at the core of every successful customer experience, from outbound content to truly understanding user interaction on the web. We are excited to see OpenDNA’s artificial intelligence technology revolutionising the way en-terprises work.”
The success of the project will allow OpenDNA to recurring revenues yearly that will be earned from software subscription license fees and professional services fees.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
